Log in to search using one of your social media accounts:

 

Prognostic Testing Patterns and Outcomes of Chronic Lymphocytic Leukemia Patients Stratified by Fluorescence in Situ Hybridization/Cytogenetics: A Real-World Clinical Experience in the Connect CLL Registry

Prognostic genetic testing can guide treatment decisions and predict outcomes for patients with chronic lymphocytic leukemia (CLL). Among 1,494 patients with CLL treated in the community setting, prognostic genetic testing was infrequently performed and outcomes were inferior for patients with unfavorable-risk disease. This highlights the importance of prognostic testing for patients with CLL to guide treatment and improve outcomes.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research

Related Links:

A Markov model was used to assess the cost-effectiveness of ibrutinib compared to obinituzumab in combination with chlorambucil for untreated patients in the United Kingdom. The results demonstrated ibrutinib not to be cost-effective. However, additional analyses demonstrated ibrutinib to be significantly cost-effective when compared to the current mode of care in which ibrutinib is administered as the second-line treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Conclusion This study shows that prognostic cytogenetic/FISH testing is infrequently performed and that patients with unfavorable-risk genetics treated with immunochemotherapy combinations have worse outcomes. This underscores the importance of performing prognostic genetic testing in all CLL patients to guide treatment. Teaser Prognostic genetic testing can guide treatment decisions and predict outcomes for patients with chronic lymphocytic leukemia (CLL). Among 1,494 patients with CLL treated in the community setting, prognostic genetic testing was infrequently performed and outcomes were inferior for patients with unfav...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We describe the clinicopathologic features of 17 patients who had a hematologic malignancy of various types, were treated, and subsequently developed a lymphoproliferative disorder (LPD). There were 10 men and 7 women with a median age of 59 years (range, 36 to 83 y). The primary hematologic neoplasms included: 5 chronic lymphocytic leukemia/small lymphocytic lymphoma, 3 plasma cell myeloma, 2 acute monoblastic leukemia, and 1 case each of mixed-phenotype acute leukemia, chronic myeloid leukemia, splenic marginal zone lymphoma, follicular lymphoma, mantle cell lymphoma, T-cell prolymphocytic leukemia, and peripheral...
Source: The American Journal of Surgical Pathology - Category: Pathology Tags: Original Articles Source Type: research
Authors: Sanna S, Satta G, Padoan M, Piro S, Gambelunghe A, Miligi L, Ferri GM, Magnani C, Muzi G, Rigacci L, Cabras MG, Angelucci E, Latte GC, Gabbas A, Ennas MG, Cocco P Abstract The aryl hydrocarbon receptor (AhR) is a transcription factor implicated in several pathways known to be relevant in lymphomagenesis. Aim of our study was to explore the link between AhR activation and risk of lymphoma subtypes. We used a Dual-Luciferase Assay(®) and a luminometer to detect the activation of the luciferase gene, in HepG2 cells transfected with a specific reporter systems, by a 50 ml serum aliquot of cases of diffuse ...
Source: International Journal of Molecular Epidemiology and Genetics - Category: Genetics & Stem Cells Tags: Int J Mol Epidemiol Genet Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Riccardo Moia, Fary Diop, Chiara Favini, Elisa Spaccarotella, Lorenzo De Paoli, Alessio Bruscaggin, Valeria Spina, Michaela Cerri, Clara Deambrogi, Ahad Ahmed Kodipad, Simone Favini, Sruthi Sagiraju, Clive Jabangwe, Francesca Romana Mauro, Ilaria Del Giudice, Francesco Forconi, Agostino Cortelezzi, Francesco Zaja, Carlo Visco, Annalisa Chiarenza, Gian Matteo Rigolin, Roberto Marasca, Marta Coscia, Omar Perbellini, Alessandra Tedeschi, Luca Laurenti, Marina Motta, Giovanni Del Poeta, Antonio Cuneo, Valte...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2017 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 17, Issue 10, Supplement Author(s): Paolo Strati, Michael J. Keating, Jan A. Burger, Susan M. O'Brien, William G. Wierda, Zeev Estrov, Gracy Zacharian, Alessandra Ferrajoli
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Bendamustine is an effective therapy with limited long-term sequelae in patients with lymphoid malignancies. Micro-Abstract Bendamustine is an effective treatment for lymphoid malignancies and its role continues to expand. To determine the long-term sequelae associated with bendamustine, 194 patients treated with bendamustine (most commonly with rituximab) were retrospectively reviewed. The rate of secondary malignancies was minimal and no therapy-related myelodysplastic syndrome or acute myelogenous leukemia were reported. No deaths from infection were attributable to bendamustine.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CLL, lenalidomide, consolidation
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
chronic lymphocytic leukemia, FCR, immunochemotherapy, molecular predictors, precision medicine
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Chronic Lymphocytic Leukemia Source Type: research
Publication date: Available online 25 September 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): S. Kersting, S.I.M. Neppelenbroek, H.P.J. Visser, M v Gelder, M.D. Levin, R. Mous, E.F.M. Posthuma, H.M. van der Straaten, A.P. Kater In recent years, considerable progress has been made in treatment of patients with chronic lymphocytic leukaemia (CLL) and new potent drugs have become available. Therefore, the CLL working party of the Dutch/ Belgium Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) framework revised the Dutch guidelines based on new studies and expert opinion of members of the work...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Chronic Leukemia | Chronic Lymphocytic Leukemia | Genetics | Hematology | Leukemia | Lymphoma | Myeloma | Study